Claret Asset Management Corp Buys 22,921 Shares of Novo Nordisk A/S (NYSE:NVO)

Claret Asset Management Corp increased its stake in Novo Nordisk A/S (NYSE:NVO) by 314.4% in the 4th quarter, Holdings Channel reports. The firm owned 30,212 shares of the company’s stock after purchasing an additional 22,921 shares during the period. Claret Asset Management Corp’s holdings in Novo Nordisk A/S were worth $2,599,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. M. Kulyk & Associates LLC grew its stake in Novo Nordisk A/S by 3.9% in the 4th quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company’s stock valued at $274,000 after buying an additional 119 shares during the last quarter. Center for Financial Planning Inc. grew its position in shares of Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock valued at $25,000 after purchasing an additional 123 shares during the last quarter. Tradewinds Capital Management LLC increased its stake in shares of Novo Nordisk A/S by 2.6% in the fourth quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company’s stock worth $429,000 after purchasing an additional 124 shares during the period. Exencial Wealth Advisors LLC lifted its position in shares of Novo Nordisk A/S by 0.5% during the 4th quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company’s stock worth $1,987,000 after purchasing an additional 124 shares during the last quarter. Finally, Indie Asset Partners LLC boosted its stake in Novo Nordisk A/S by 4.2% during the 4th quarter. Indie Asset Partners LLC now owns 3,128 shares of the company’s stock valued at $269,000 after purchasing an additional 126 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on NVO shares. BMO Capital Markets reiterated a “market perform” rating and set a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Finally, Stifel Nicolaus cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $135.00.

Novo Nordisk A/S Trading Down 7.8 %

NVO stock opened at $57.99 on Friday. Novo Nordisk A/S has a 1-year low of $57.28 and a 1-year high of $148.15. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The business’s 50 day moving average is $75.52 and its 200-day moving average is $91.71. The firm has a market cap of $260.23 billion, a P/E ratio of 17.63, a P/E/G ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were given a $0.7874 dividend. The ex-dividend date of this dividend was Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a yield of 1.2%. Novo Nordisk A/S’s payout ratio is 49.54%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.